{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:30:43Z","timestamp":1760783443953},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,9,8]],"date-time":"2011-09-08T00:00:00Z","timestamp":1315440000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00280-011-1729-2","type":"journal-article","created":{"date-parts":[[2011,9,7]],"date-time":"2011-09-07T11:05:31Z","timestamp":1315393531000},"page":"547-554","source":"Crossref","is-referenced-by-count":47,"title":["A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies"],"prefix":"10.1007","volume":"69","author":[{"given":"Julie","family":"Bauman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Verschraegen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Belinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Muller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Rutledge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fekrazad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meera","family":"Ravindranathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Joon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennie","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,8]]},"reference":[{"key":"1729_CR1","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000279388","volume":"77","author":"G Lurje","year":"2009","unstructured":"Lurje G, Lenz H (2009) EGFR signaling and drug discovery. Oncology 77:400\u2013410","journal-title":"Oncology"},{"key":"1729_CR2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","volume":"19","author":"DS Salomon","year":"1994","unstructured":"Salomon DS, Brandt R, Ciardiello F, Normanno N (1994) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183\u2013232","journal-title":"Crit Rev Oncol Hematol"},{"issue":"25","key":"1729_CR3","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1200\/JCO.2006.07.2587","volume":"24","author":"CH Chung","year":"2006","unstructured":"Chung CH et al (2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. JCO 24(25):4170\u20134176","journal-title":"JCO"},{"key":"1729_CR4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/jso.2930510304","volume":"51","author":"AW Hemming","year":"1992","unstructured":"Hemming AW, David NL, Kluftinger A et al (1992) Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 51:147\u2013152","journal-title":"J Surg Oncol"},{"key":"1729_CR5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/00006676-200407000-00061","volume":"29","author":"S Ueda","year":"2004","unstructured":"Ueda S, Ogata S, Tsuda H et al (2004) The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness; poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 29:e1\u2013e8","journal-title":"Pancreas"},{"key":"1729_CR6","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. NEJM 350:2129\u20132139","journal-title":"NEJM"},{"key":"1729_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp0903765","volume":"361","author":"R Rosell","year":"2009","unstructured":"Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. NEJM 361:1\u201310","journal-title":"NEJM"},{"issue":"397","key":"1729_CR8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1158\/1078-0432.397.11.1","volume":"11","author":"ER Camp","year":"2005","unstructured":"Camp ER, Summy J, Bauer TW et al (2005) Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Can Research 11(397):397\u2013405","journal-title":"Clin Can Research"},{"issue":"21","key":"1729_CR9","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"JG Herman","year":"2003","unstructured":"Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. NEJM 349(21):2042\u20132054","journal-title":"NEJM"},{"key":"1729_CR10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg816","volume":"3","author":"PA Jones","year":"2002","unstructured":"Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev 3:415\u2013427","journal-title":"Nat Rev"},{"issue":"4","key":"1729_CR11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2009.23.4781","volume":"28","author":"L Shen","year":"2010","unstructured":"Shen L, Kantarjian H, Gui Y et al (2010) DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. JCO 28(4):605\u2013613","journal-title":"JCO"},{"key":"1729_CR12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). JNCI 92:205\u2013216","journal-title":"JNCI"},{"issue":"6","key":"1729_CR13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","volume":"96","author":"GJ Rustin","year":"2004","unstructured":"Rustin GJ, Quinn M, Thigpen T et al (2004) New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). JNCI 96(6):487\u2013488","journal-title":"JNCI"},{"issue":"2","key":"1729_CR14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Pereira JR, Ciuleanu T et al (2005) Erlotinib in previously treated non-small cell lung cancer. NEJM 353(2):123\u2013132","journal-title":"NEJM"},{"key":"1729_CR15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","volume":"8","author":"MH Cohen","year":"2003","unstructured":"Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R (2003) FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8:303\u2013306","journal-title":"Oncologist"},{"key":"1729_CR16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/DDDT.S3143","volume":"4","author":"CE Vigil","year":"2010","unstructured":"Vigil CE, Martins-Santos T, Garcia-Manero G (2010) Safety and efficacy of azacitidine in myelodysplastic syndromes. Drug Des Dev Ther 4:221\u2013229","journal-title":"Drug Des Dev Ther"},{"key":"1729_CR17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.23607","volume":"123","author":"C Stresemann","year":"2008","unstructured":"Stresemann C, Lyko F (2008) Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 123:8\u201313","journal-title":"Int J Cancer"},{"issue":"1","key":"1729_CR18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","volume":"20","author":"PA Jones","year":"1980","unstructured":"Jones PA, Taylor SM (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20(1):85\u201393","journal-title":"Cell"},{"issue":"1","key":"1729_CR19","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/ncponc0354","volume":"2S","author":"SB Baylin","year":"2005","unstructured":"Baylin SB (2005) DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2S(1):S4\u2013S11","journal-title":"Nat Clin Pract Oncol"},{"issue":"2","key":"1729_CR20","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/0008-5472.CAN-10-3184","volume":"71","author":"SA Belinsky","year":"2011","unstructured":"Belinsky SA, Grimes MJ, Picchi MA et al (2011) Combination therapy with Vidaza and Entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res 71(2):454\u2013462","journal-title":"Cancer Res"},{"key":"1729_CR21","unstructured":"Juergens R, Vendetti F, Wrangle J et al (2010) A phase II study of combination epigenetic therapy in advanced non-small cell lung cancer. American Association for Cancer Research 101st Annual Meeting, 17\u201321 April 2010. Abstract LB-411"},{"key":"1729_CR22","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"JG Herman","year":"2003","unstructured":"Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042\u20132054","journal-title":"N Engl J Med"},{"key":"1729_CR23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrc1799","volume":"6","author":"SB Baylin","year":"2006","unstructured":"Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer\u2014a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107\u2013116","journal-title":"Nat Rev Cancer"},{"key":"1729_CR24","doi-asserted-by":"crossref","first-page":"11891","DOI":"10.1073\/pnas.95.20.11891","volume":"95","author":"SA Belinsky","year":"1998","unstructured":"Belinsky SA, Nikula KJ, Palmisano WP et al (1998) Aberrant methylation of p16 INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95:11891\u201311896","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1729_CR25","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/cncr.23312","volume":"112","author":"Y Wang","year":"2008","unstructured":"Wang Y, Zhang D, Zheng W et al (2008) Multiple gene methylation of non-small cell lung cancers evaluated with 3-dimensional microarray. Cancer 112(6):1325\u20131336","journal-title":"Cancer"},{"issue":"6","key":"1729_CR26","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/mc.20621","volume":"49","author":"WB Liu","year":"2010","unstructured":"Liu WB, Liu JY, Ao L et al (2010) Epigenetic silencing of cell cycle regulatory genes during 3-methyl cholanthrene and diethylnitrosamine-induced multistep rat lung cancer. Mol Carcinog 49(6):556\u2013565","journal-title":"Mol Carcinog"},{"issue":"5","key":"1729_CR27","first-page":"1157","volume":"31","author":"R Noro","year":"2007","unstructured":"Noro R, Gemma A, Miyanaga A et al (2007) PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Oncol 31(5):1157\u20131163","journal-title":"Int J Oncol"},{"key":"1729_CR28","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMoa0706550","volume":"358","author":"MV Brock","year":"2008","unstructured":"Brock MV, Hooker CM, Ota-Machida E et al (2008) DNA methylation markers and early recurrence in stage I lung cancer. NEJM 358:1118\u20131128","journal-title":"NEJM"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1729-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1729-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1729-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T01:29:44Z","timestamp":1712798984000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1729-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,8]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["1729"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1729-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,8]]}}}